Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow- up results from JAVELIN Renal 101.

被引：13

作者：

Haanen, John B. A. G.

Larkin, James

Choueiri, Toni K.

Albiges, Laurence

Rini, Brian I.

Atkins, Michael B.

Schmidinger, Manuela

Penkov, Konstantin

Thomaidou, Despina

Wang, Jing

Mariani, Mariangela

Di Pietro, Alessandra

Motzer, Robert J.

机构：

[1] Netherlands Canc Inst, Amsterdam, Netherlands

[2] Royal Marsden Hosp NHS Fdn Trust, London, England

[3] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA

[4] Univ Paris Sud, Dept Canc Med, Gustave Roussy Canc Campus, Boston, MA USA

[5] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[6] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA

[7] Med Univ Vienna, Vienna, Austria

[8] Private Med Inst Euromedservice, St Petersburg, Russia

[9] Pfizer Hellas, Athens, Greece

[10] Pfizer, Cambridge, MA USA

[11] Pfizer Srl, Milan, Italy

[12] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4574

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4574

引用

页数：4